The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane

Kidney International

Volumn 66, Issue 1, 2004, Pages 408-418

  Williams, John D ^a   Topley, Nicholas ^b   Craig, Kathrine J ^b   Mackenzie, Ruth K ^b   Pischetsrieder, Monika ^b   Lage, Cristina ^b   Passlick Deetjen, Jutta ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Biocompatibility; Cancer antigen 125; Glucose degradation products; pH neutral; Residual renal function; Ultrafiltration

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; BUFFER; CA 125 ANTIGEN; GLUCOSE DEGRADATION PRODUCT; HYALURONIC ACID; IMIDAZOLINE; LACTIC ACID; PERITONEAL DIALYSIS FLUID; PROCOLLAGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACIDITY; ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; CIRCULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; EFFLUENT; EVALUATION; EXPOSURE; FEMALE; FUNCTION TEST; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOASSAY; IN VIVO STUDY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEMBRANE; METHODOLOGY; MULTICENTER STUDY; PERITONEUM; PH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE; SERUM; STANDARD; ULTRAFILTRATION;

EID: 3042720430     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00747.x     Document Type: Article

References (56)

1. VAN BIESEN W, VANHOLDER R, DEBACQUER D, et al: Comparison of survival on CAPD and haemodialysis: Statistical pitfalls. Nephrol Dial Transplant 15:307-311, 2000
2. VAN BIESEN W, VANHOLDER R, LAMEIRE N: The role of peritoneal dialysis as the first-line renal replacement modality. Perit Dial Int 20:375-383, 2000
3. COLES GA, WILLIAMS JD: What is the place of peritoneal dialysis in the integrated treatment of renal failure? Kidney Int 54:2234-2240, 1998
4. DAVIES SJ, BRYAN J, PHILLIPS L, RUSSELL GI: Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11:498-506, 1996
5. DAVIES SJ, PHILLIPS L, GRIFFITHS AM, et al: What really happens to people on long-term peritoneal dialysis? Kidney Int 54:2207-2217, 1998
6. TOPLEY N: Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions. Adv Ren Replace Ther 5:179-184, 1998
7. RIPPE B, SIMONSEN O, HEIMBURGER O, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59:348-357, 2001
8. JONES S, HOLMES CJ, KREDIET RT, et al: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 59:1529-1538, 2001
9. DAVIES SJ, PHILLIPS L, NAISH PF, RUSSELL GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 12:1046-1051, 2001
10. HONDA K, NITTA K, HORITA S, et al: Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 14:1541-1549, 1999
11. MIYATA T, HORIE K, UEDA Y, et al: Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 58:425-435, 2000
12. COMBET S, MIYATA T, MOULIN P, et al: Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis [in process citation]. J Am Soc Nephrol 11:717-728, 2000
13. WIESLANDER AP, NORDIN MK, KJELLSTRAND PTT, BOBERG UC: Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 40:77-79, 1991
14. WIESLANDER AP: Cytotoxicity of peritoneal dialysis fluid-is it related to glucose breakdown products. Nephrol Dial Transplant 11:958-959, 1996
15. WIESLANDER AP, ANDREN AHG, NILSSON-THORELL C, et al: Are aldehydes in heat sterilised peritoneal dialysis fluids toxic in vitrol Perit Dial Int 15:348-352, 1995
16. NAKAYAMA M, KAWAGUCHI Y, YAMADA K, et al: S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 51:182-186, 1997
17. WITOWSKI J, WISNIEWSKA J, KORYBALSKA K, et al: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 12:2434-2441, 2001
18. WITOWSKI J, KORYBALSKA K, WISNIEWSKA J, et al: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 11:729-739, 2000
19. WIESLANDER AP, NORDIN MK, MARTINSON E, et al: Heat sterilised PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. Clin Nephrol 39:343-348, 1993
20. MORGAN LW, WIESLANDER A, DAVIES M, et al: Glucose degradation products (GDP) retard re-mesothelialisation independently of D-glucose concentration. Kidney Int 64:1854-1866, 2003
21. MORTIER S, DE VRIESE AS, MCLOUGHLIN RM, et al: Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 14:1296-1306, 2003
22. MORTIER S, DE VRIESE AS, VAN DE VOORDE J, et al: Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: Role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 13:480-489, 2002
23. HENDERSON IS: Composition of peritoneal dialysis solutions: Potential hazards. Blood Purif 7:86-94, 1989
24. TAUER A, KNERR T, NIWA T, SCHAUB TP, et al: In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 280:1408-1414, 2001
25. THORNALLEY PJ, LANGBORG A, MINHAS HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344(Pt 1):109-116, 1999
26. LINDEN T, FORSBACK G, DEPPISCH R, et al: 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 18:290-293, 1998
27. LINDEN T, COHEN A, DEPPISCH R, et al: 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 62:697-703, 2002
28. ZEIER M, SCHWENGER V, DEPPISCH R, et al: Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63:298-305, 2003
29. MELLINGHOFF AC, REININGER AJ, WUERTH JP, et al: Formation of plasma advanced glycosylation end products (AGEs) has no influence on plasma viscosity. Diabet Med 14:832-836, 1997
30. NIWA T, KATSUZAKI T, MIYAZAKI S, et al: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99:1272-1280, 1997
31. CHICHIBU K, MATSUURA T, SHICHIJO S, YOKOYAMA MM: Assay of serum hyaluronic acid in clinical application. Clin Chim Acta 181:317-323, 1989
32. GOTCH FA, LIPPS BJ, KEEN ML, PANLILIO F: Computerized urea kinetic modeling to prescribe and monitor delivered Kt/V (pKt/V, dKt/V) in peritoneal dialysis. Fresenius Randomized Dialysis Prescriptions and Clinical Outcome Study (RDP/CO). Adv Perit Dial 12:43-45, 1996
33. COOKER LA, LUNEBURG P, FAICT D, et al: Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int 17:373-378, 1997
34. RIPPE B, SIMONSEN O, WIESLANDER A, LANDGREN C: Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int 17:27-34, 1997
35. HO-DAC-PANNEKEET MM, HIRALALL JK, STRUIJK DG, KREDIET RT: Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 51:888-893, 1997
36. KREDIET RT: Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 21:560-567, 2001
37. O'BRIEN TJ, BEARD JB, UNDERWOOD LJ, et al: The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol 22:348-366, 2001
38. YAMAGATA K, TOMIDA C, KOYAMA A: Intraperitoneal hyaluronan production in stable continuous ambulatory peritoneal dialysis patients. Perit Dial Int 19:131-137, 1999
39. YUNG S, COLES GA, DAVIES M: IL-1β, a major stimulator of hyaluronan synthesis in vitro of human peritoneal mesothelial cells: Relevance to peritonitis in CAPD. Kidney Int 50:1337-1343, 1996
40. ZWEERS MM, DE WAART DR, SMIT W, et al: Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med 134:124-132, 1999
41. ZWEERS MM, STRUIJK DG, SMIT W, KREDIET RT: Vascular endothelial growth factor in peritoneal dialysis: A longitudinal follow-up. J Lab Clin Med 137:125-132, 2001
42. FIEREN MWJA, VAN DEN BEMD GJ, BONTA IL: Peritoneal macrophages from patients on CAPD show an increased capacity to secrete interleukin-1 beta during peritonitis. Adv Perit Dial 6:120-122, 1990
43. WITOWSKI J, JÖRRES A, KORYBALSKA K, et al: Glucose degradation products in peritoneal dialysis fluids: Do they harm? Kidney Int (Suppl):S148-151, 2003
44. SCHWENGER V, ZEIER M, HENLE T, RITZ E: Advanced glycation endproducts (AGEs) as uremic toxins. Nahrung 45:172-176, 2001
45. SINOHAL MK, BHASKARAN S, VIDGEN E, et al: Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 20:429-438, 2000
46. SHEMIN D, BOSTOM AG, LAMBERT C, et al: Residual renal function in a large cohort of peritoneal dialysis patients: Change over time, impact on mortality and nutrition. Perit Dial Int 20:439-444, 2000
47. WIECZOROWSKA-TOBIS K, BRELINSKA R, WITOWSKI J, et al: Evidence of less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 24:48-57, 2004
48. STEINHAUER HB, SCHOLLMEYER P: Prostaglandin mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. Kidney Int 29:584-590, 1986
49. COLES GA, O'DONOGHUE DJ, PRITCHARD N, et al: A controlled trial of two bicarbonate-containing dialysis fluids for CAPD - Final report. Nephrol Dial Transplant 13:3165-3171, 1998
50. TRANAEUS A: Group TBls: A long term study of a bicarbonate/lactate based peritoneal dialysis solution - Clinical benefits. Perit Dial Int 20:516-523, 2000
51. MACTIER RA, SPROSEN TS, GOKAL R, et al: Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 53:1061-1067, 1998
52. TERMORSHUIZEN F, KOREVAAR JC, DEKKER FW, et al: The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands cooperative study on the adequacy of dialysis (Necosad)-2. Am J Kidney Dis 41:1293-1302, 2003
53. CHUNG SH, HEIMBURGER O, STENVINKEL P, et al: Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 23:174-183, 2003
54. LO WK, HO YW, LI CS, et al: Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int 64:649-656, 2003
55. BARGMAN JM, THORPE KE, CHURCHILL DN: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12:2158-2162, 2001
56. PANIAGUA R, AMATO D, VONESH E, et al: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13:1307-1320, 2002